Yes, Prostate Cancer (PCa) is not contagious. Radiation treatment with Brachytherapy (seeds), usually recommends a short period of condom use immediately after seeding.
This is a precautionary measure that allows time for the "seeds" to firmly adhere to the body tissue, so they are not likely to travel elsewhere in the body or be expelled through the urine or ejaculate. Such movement is relatively rare. - John@NEWpca.org (aka) az4peaksView Thread
Hi an, - The first thing to do is to determine whether these elevations are due to a recurrence or represent a benign PSA "bounce". The well documented and temporary "bounce" is experienced by about one-third of men receiving Brachytherapy. It usually occurs between 1 and 2 years following the implanting of the "seeds" (ave=18 months).
Monitoring is the only way to determine the cause of post-treatment elevations and your attending Physician should be able to help you determine the actual cause. The good news is that if it does turn out to be a "bounce, rather than a recurrence, studies have shown it to have no deleterious effect on the the eventual outcome of the treatment.
Hi Chuck, - Older men (like us) nearly always have "suspect" areas on bone scans, so lets hope that the MRI will clarify that the lesion is an old injury or arthritic changes.
If, however, it does turn out to be a metastasis from PCa, it it would still likely be treatable as as a chronic condition and it wouldn't change my optimistic observation about your probable life expectancy (as affected by PCa).
It is nice that you, like me, remember those who have not been as fortunate in their PCa battles. When we lost Bill, we not only lost one of the "good" guys of the world but, also, an unbiased fountain of knowledge that was, and is, matched by very few. AND Dave was one of the most compassionate and caring people you will ever meet. Both gone too soon and missed greatly, by me.
I wish you the very best my friend and until you tell me differently, I'll continue to hope that the "suspect'' area on your Imaging, turns out to be benign in origin.
[a name="pageTitle" style="color: rgb(0, 0, 102); ">GTx Announces Clinical Hold on Clinical Trials Evaluating Capesaris for First and Second Line Treatments of Advanced Prostate Cancer MEMPHIS, Tenn.--(BUSINESS WIRE)--Feb 21, 2012 - GTx, Inc. (Nasdaq: GTXI) announced today that the U.S. Food and Drug Administration (FDA) notified the Company in a telephone call on Friday, February 17, 2012, that the agency has placed a clinical hold on the Company's clinical trials evaluating CapesarisÂ® (GTx-758) for primary (first line) androgen deprivation therapy for advanced prostate cancer and secondary (second line) hormonal treatment. A clinical hold is a notification issued by the FDA to the trial sponsor to delay a clinical trial or suspend an ongoing clinical trial.
The clinical hold affects GTx's Phase II loading dose finding clinical trial and its Phase IIb maintenance dose finding clinical trial, as well as its Phase II clinical trial in men with castration resistant prostate cancer. The clinical hold, which is effective immediately, follows the Company's reports to the FDA of an increased risk of venous thromboembolic events, or blood clots, in subjects treated with Capesaris at the doses studied (1000 mg and higher) and the Company's request to discuss changes in its clinical development program. GTx has suspended further enrollment into these studies and has notified clinical sites to discontinue treatment of subjects.
The Company believes there may be a path forward to develop Capesaris at lower doses to treat men with metastatic hormone sensitive prostate cancer or castration resistant prostate cancer. The Company will work with the FDA to determine the appropriate course of action to evaluate Capesaris in these patient populations. View Thread
Hi Chuck, - As you know, I have followed your journey for several years and we have had direct communication on occasion.
It is good to see you are still kicking around and that your rather conservative treatment approach has been reasonably successful in maintaining your quality of life and that you have reached 76 y/o without greatly significant problems to date.
According to the SS actuarial tables a typical U.S. Male who is 76 has about 10 years of remaining life expectancy (ON AVERAGE), so this is the pragmatic time-frame to be considered, when considering treatment decisions.
Hormone Therapy (HT), usually starting with ADT, has its own set of side effects (morbidity) and I know that in the past, you have had strong feelings about preserving your quality of life. Intermittent HT usually provides a better Q of L , during the "off" periods than does continuous HT. It seems to me that you and your professional advisors are in harmony about your treatment and that, I believe, is important for your well being.
Although it is a "crap-shoot" for each and every one of us, individually, it appears to me that you have a good chance of making the actuarial life expectancy. Good luck in whatever you decide and enjoy life, as best you can. Best personal regards! - John@newPCa.org (aka) az4peaksView Thread
TO ALL: - Although a vast majority of " experts" have long agreed that the formula used to calculate the Medicare payments for Physicians is, AND LONG HAS BEEN, badly flawed and needs a permanent fix, none has been formulated.
Instead, for several consecutive years Congress has chosen to, at least annually, adopt a "temporary" fix of 12 months or less, that has averted cuts in such payments. These cuts have accumulated until, if enacted on March !st, 2012 as was scheduled, it would have amounted to an overall reduction in payments to Physicians, of over 27%. This is true, even though reliable data establishes that during the same time-period M.D's expenses have increased.
So, once again, instead of coming up with a real solution, Congress has again chosen to pass a temporary fix that averts the cuts for another 10 months at the end of which, the problem will again require some congressional action. - John@newPCa.org (aka) az4peaks
Here is todays announcement:
"Congress approves measure averting 27 percent physician cut through 2012
A House-Senate Conference Committee tasked with identifying a compromise to avoid the pending 27.4 percent Medicare physician payment cut reached a 10-month deal that would maintain current physician payment rates through the end of the year.
The measure was approved this afternoon by both the House and Senate. The measure now goes to President Obama for his signature. The President is expected to sign the bill"View Thread
Hi Tengoku, - If this is a general examination, it is not unusual to include a DRE (Digital Rectal Exam). Obviously, they are not specifically examining the Prostate, since there is none present, but there are other reasons for doing a DRE in a complete examination.
Urologists,usually, do not routinely do DRE's after the Prostate has been removed, since their DRE is done to feel the Prostate, which no longer exists.
Most feel that the monitoring PSA is far more sensitive than the DRE, in detecting any potential PCa recurrence. This protocol, of course, can vary by individual Physician and Specialty.
Hope this helps! - John@newPCa.org (aka) az4peaksView Thread
Hi ntredme, - It is always a shock to hear that one has Cancer and Prostate Cancer (PCa) is no exception. But Cancer comes in many forms and many stages and they are not all the same by any means.. Without more information, any answer that you receive, as it may apply to your specific situation will be pure speculation and unreliable. But, IN GENERAL, I can assure you that the Gleason SCORE of (3 3) =6 is the lowest (most favorable) that should appear on a Biopsy Pathology Report, since the modern protocol was adopted by "standard setting "Pathology governing bodies across the world in 2006. Although the single most important element in determining the probable aggressiveness of the disease, it ALONE is not able to assess the clinical STAGE of the disease, its proliferation and/or prognosis. Such items as the number and percentage of PCa found in individual core samples, the total number of samples obtained and the other items mentioned in the following article can be very important in assessing the extent and significance of the disease that is present. You need to learn them in your case. The four treatment options you were given are all likely to be valid, along with others, but, here, patient age can be extremely significant in the considerations, along with the items previously mentioned. Read this article for more helpful information. What EVERY newly diagnosed Prostate Cancer (PCa) patient needs to know! by John E. Holliday, FACMPE
First, ALL Prostate Cancer patients should determine the basic diagnostic realities of their specific disease and understand its relative significance. In my opinion, EVERY newly diagnosed PCa patient needs to gather the following data, to even START your considerations.
I would suggest you begin by acquiring the following diagnostic results.
(1) What was my last PSA prior to diagnosis? (If available, previous PSA readings with dates are helpful). Either get copies or write them down.
(2) What is my complete Gleason SCORE? (Primary Secondary GRADES = Gleason SCORE) ie: (3 3)= 6, (4 3)= 7, etc.
(3) What is the clinical STAGE assigned to my Prostate Cancer? (ie: T1c, T2a, T3b, etc.)
(4) Obtain a copy of the Pathology Report from the Biopsy, which should be available from your Physician. It can contain helpful information, now and in the future. Keep it for your records!
These 4 items, when coupled with your age and ethnicity, will provide the BASIC information necessary to BEGIN to truly understand what the status of your disease is thought to be, at the time of your diagnosis.
When embarking on any journey, when trying to determine the route you want to take, you must first determine where you are NOW, and this is that START!
Without knowing this basic information, and understanding its relevance, informed decisions cannot be made and the applicable relevance of gathered information remains undetermined.
If a man has been diagnosed with early stage disease, as approximately 3 out of 4 men presenting today are, there is usually no urgent reason or necessity, to make a hurried, uninformed decision.
If you feel rushed, pressured or remain uncertain as to whether you know enough to feel relatively comfortable with your choice, wait until you are.
Obviously, however, there is no reason to unnecessarily prolong the decision making process beyond that reasonable time frame needed to acquire, and to understand, such information. Delays should NOT be the result of unwarranted procrastination.
With this basic information, the educational learning process can begin and more INFORMED decisions are then possible.
I will be happy to answer specific questions that anyone may have. - John@newPCa.org (aka) az4peaks View Thread
Hi an, - The success of secondary radiation as a potential "cure" for Prostate Cancer (PCa) following "failed" surgery, is largely dependent on whether the source of the recurrence as demonstrated by an "elevated" post-surgical PSA blood test (>0.1 or 0.2 ng/ml), is "localized" or "systemic" in origin.
Unfortunately, this is seldom easily determined and therefor, most often, a subjective judgment has to be made, based on a variety of diagnostic information that should be available. These include, but are not limited to, age, the PSA at the time of treatment and now, time from treatment to the recurrence, did the monitoring PSA results ever reach traditional, clinically "undetectable" levels (<0.1 ng/ml) and the findings contained in the post-surgical Pathology Report such as Gleason Score, and extent of disease/location.
Systemic disease refers to malignant cells that have escaped the Prostate and invaded the blood/lymph systems and are circulating within the body or haven taken root elsewhere, in the form of distant metastases. If such cells exist at a size and/or Stage that is unable to be detected with todays technology they are often referred to as "micro" cells or metastases.
The potential for their existence increases in direct proportion to the "favorable" or "unfavorable" levels of the items mentioned above. When determining the likelihood of "localized" disease, which is the only kind curatively effective by any treatment but Hormone Therapy (HT) and/or Chemo, earlier recurrence is less favorable than more prolonged time-frames. As a group, patients with less favorable (over-all) positive margins, actually have better statistical success rates with Salvage Radiation Therapy (SRT) than do those with more desirable (over-all) negative surgical margins.
But the effects on decision making should be the conclusions reached by weighing ALL of the diagnostic "clues" involved and the potential risk/reward ratio that they imply. So what do you do if it can't be determined, WITH CERTAINTY, whether the recurrence is localized or not?
You then weigh your POSSIBILITY for a potential "cure" based upon the above, versus the reality of (widely varying, but sometimes prolonged) remission control offered by HT against their potential for increased morbidity (side effects).
These are not easy decisions and professional guidance can help sort through the considerations and options, but it comes down to the fact that secondary treatment for, hopefully, localized disease is presently your last chance for "cure" as opposed to efforts to control a chronic disease. Its potential for success, in your INDIVIDUAL situation should be the determining factor, since statistical results are determined by data from large groups of men and cannot be directly transferred to INDIVIDUAL patients.